This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Jizhou Wu
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background:This study aimed to evaluate the renal safety of telbivudine(LdT) and entecavir(ETV) in chronic hepatitis B (CHB) patients with renal impairment.
Methods:Studies published from January 1, 2010 to February 1, 2020 were identified using the PubMed, Web of Science, Scopus,Cochrane Library,ClinicalTrials.gov and CNKI (China National Knowledge Infrastructure).Finally,a total of 7 studies (1088 patients) with eGFR outcomes were retrieved and analyzed.The meta-analysis was conducted using RevMan 5.3.
Results:The results of the 7 eligible studies analyzed suggested that the eGFR was both improved after LdT and ETV treatment.Compared with the baseline level,the eGFR was significantly improved with LdT (7.02 mL/min/1.73 m2 ) while slightly improved with ETV (1.72 mL/min/1.73 m2 ) after 1 years of treatment. The eGFR was significantly higher in the LdT therapy group than in the ETV group after 6 months(RR = 4.63, 95%CI: 0.73–8.54,Z = 2.33; P = 0.02)，1 year(RR = 3.35, 95%CI: 1.18–5.52,Z = 3.02; P = 0.002)，and 2 years(RR = 11.00, 95%CI: 4.84–17.15,Z = 3.50; P = 0.0005) of treatment .
Conclusion: Our meta-analysis of current evidence demonstrated that in CHB patients with impaired renal function, LdT could be the better choice than ETV.
Keywords
Chronic hepatitis B;Telbivudine, Entecavir;Nucleos(t)ide Analogues;Renal Function;
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 23 Jul, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Virology
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research
Jizhou Wu
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 23 Jul, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Virology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background:This study aimed to evaluate the renal safety of telbivudine(LdT) and entecavir(ETV) in chronic hepatitis B (CHB) patients with renal impairment.
Methods:Studies published from January 1, 2010 to February 1, 2020 were identified using the PubMed, Web of Science, Scopus,Cochrane Library,ClinicalTrials.gov and CNKI (China National Knowledge Infrastructure).Finally,a total of 7 studies (1088 patients) with eGFR outcomes were retrieved and analyzed.The meta-analysis was conducted using RevMan 5.3.
Results:The results of the 7 eligible studies analyzed suggested that the eGFR was both improved after LdT and ETV treatment.Compared with the baseline level,the eGFR was significantly improved with LdT (7.02 mL/min/1.73 m2 ) while slightly improved with ETV (1.72 mL/min/1.73 m2 ) after 1 years of treatment. The eGFR was significantly higher in the LdT therapy group than in the ETV group after 6 months(RR = 4.63, 95%CI: 0.73–8.54,Z = 2.33; P = 0.02)，1 year(RR = 3.35, 95%CI: 1.18–5.52,Z = 3.02; P = 0.002)，and 2 years(RR = 11.00, 95%CI: 4.84–17.15,Z = 3.50; P = 0.0005) of treatment .
Conclusion: Our meta-analysis of current evidence demonstrated that in CHB patients with impaired renal function, LdT could be the better choice than ETV.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Loading...